News Articles

Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing INGELHEIM, Germany -Tuesday 29 October 2019

Results were presented from the company’s pan-KRAS program including BI 1701963, which is being investigated alone and in combination with MEK inhibition in an ongoing Phase I clinical study in cancer patients Around 15% off all cancers can potentially be blocked by this compound,...

Boehringer Ingelheim Announces First Patient Enrolled in Phase II Trial of Novel Cystic Fibrosis Treatment... -Wednesday 16 October 2019

I(BUSINESS WIRE)-- Boehringer Ingelheim today announced the first patient enrolled in its Phase II clinical trial BALANCE-CFTM 1 to evaluate a new potential treatment for cystic fibrosis.1,2 The trial will investigate how different doses of the compound, an inhaled epithelial sodium channel...

New data reinforces benefits of Spiolto® Respimat® in improving patient outcomes -Tuesday 1 October 2019

(BUSINESS WIRE)-- Boehringer Ingelheim announced Spiolto® (tiotropium/olodaterol) Respimat® data being presented at the European Respiratory Society (ERS) 2019 Congress. The results show the benefits of tiotropium/olodaterol in improving symptoms and lung function as well as patients’...

INBUILD® meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing... -Monday 30 September 2019

New data showed positive effect of nintedanib on slowing decline of lung function in a broad range of fibrosing interstitial lung diseases with a progressive phenotype1 Phase III results published in the New England Journal of Medicine and to be presented at the European Respiratory Society...

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal... -Friday 20 September 2019

(BUSINESS WIRE)-- Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases. By combining Inflammasome’s unique intravitreal (IVT) drug...

Consistent cardiovascular benefits shown with empagliflozin treatment regardless of the number of controlled... -Thursday 19 September 2019  

Post-hoc analysis of the EMPA-REG OUTCOME® trial in adults with type 2 diabetes and established cardiovascular disease examined the cardiovascular benefits of empagliflozin based on the number of cardiovascular risk factor goals achieved.1 Findings from the post-hoc analysis were presented...

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound -Wednesday 4 September 2019

(BUSINESS WIRE)-- Boehringer Ingelheim and Lupin Limited (Lupin) today announced a licensing, development and commercialization agreement for Lupin’s MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers. The partnership aims to develop...

Anniversary of the pivotal RE-LY® trial marks a decade of innovation for stroke prevention in AF... -Friday 30 August 2019

(BUSINESS WIRE)-- Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication1-3 recognising the contribution made in the decade since by patients, healthcare professionals (HCPs) and researchers. In the fifty years prior, warfarin had been the standard of...

Boehringer Ingelheim and MD Anderson form unique Virtual Research and Development Center to rapidly advance new cancer... -Monday 12 August 2019

(BUSINESS WIRE)-- Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a new multi-year partnership to conduct collaborative research to rapidly advance therapies for various types of cancers, including gastrointestinal and lung cancers. The establishment of...

Updated real-world data shows Giotrif®/Gilotrif® (afatinib) followed by osimertinib... -Friday 2 August 2019

• Sequential afatinib and osimertinib was associated with encouraging time on treatment and overall survival in patients with EGFR T790M-positive NSCLC, especially in patients with Del19 mutation • Updated analysis of the observational GioTag study is published today in Future...

Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their... -Tuesday 11 June 2019

Boehringer Ingelheim and University of Dundee achieve milestone in collaboration aimed at developing novel protein degradation medicines Results published in Nature Chemical Biology showcase the use of the broadly applicable structure-based PROTAC design approach to discover highly potent...

Network of 1,500 Stroke-Ready Clinics across Europe -Thursday 23 May 2019

(BUSINESS WIRE)-- The Angels Initiative announced today at the European Stroke Organisation Conference (ESOC) 2019 in Milan that their three-year goal to create a network of 1,500 stroke-ready centres and hospitals across Europe has been achieved. The Angels Initiative is a unique healthcare...

Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis... -Monday 20 May 2019

Results of pivotal Phase III SENSCIS® trial published today in the New England Journal of Medicine (NEJM) and presented at the American Thoracic Society Conference in Dallas, USA Interstitial lung disease (ILD) is a key driver of mortality in people living with systemic sclerosis (SSc) –...

Financial year 2018: Boehringer Ingelheim grows and invests -Wednesday 17 April 2019

(BUSINESS WIRE)-- The research-driven pharmaceutical company Boehringer Ingelheim ended 2018 with net sales of 17.5 billion euros. Adjusted for currency effects, as well as one-off effects due to the asset swap with Sanofi in 2017, net sales grew by 4 per cent. At 3.2 billion euros (+2.8%), R&D...

Independent large real-world study comparing NOACs in AF-patients -Tuesday 16 April 2019

A recently published large retrospective comparative study investigated stroke, bleeding and mortality risks in older US Medicare patients treated with commonly marketed oral anticoagulants for non-valvular atrial fibrillation1 Results of the real-world study showed that Pradaxa®...

New post-hoc analysis of EMPA-REG OUTCOME® examined cost-effectiveness of empagliflozin versus standard... -Monday 15 April 2019  

Empagliflozin, in addition to standard of care, has the potential to improve economic outcomes for people with type 2 diabetes and established cardiovascular disease who also have diabetic kidney disease, from a US payer perspective1 Cost effective analysis used modeling and simulations...

Boehringer Ingelheim Launches the First-Ever Registered Stem Cell-Based Veterinary Medicine -Tuesday 9 April 2019  

(BUSINESS WIRE)-- Boehringer Ingelheim launches Arti-Cell® Forte in Europe for the ‘reduction of mild to moderate recurrent lameness associated with non-septic joint inflammation in horses’. Equine lameness is truly common and impacts horse performance as well as equine welfare1. Current...

Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD... -Friday 29 March 2019

New molecular platform to access intracellular targets across a broad range of tumor cell types Opens up new range of therapeutic opportunities for difficult-to-treat cancers (BUSINESS WIRE)-- Boehringer Ingelheim today announced that it acquired ICD Therapeutics. The acquisition...

Initial results from the EMPRISE real-world study of empagliflozin compared with DPP-4 inhibitors presented at ACC.19... -Thursday 28 March 2019  

(BUSINESS WIRE)-- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced initial results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world evidence study that show that empagliflozin is associated with a 22 percent relative risk reduction in all-cause...

Boehringer Ingelheim's novel antibody shows potential to transform treatment of rare form of psoriasis -Thursday 7 March 2019

(BUSINESS WIRE)-- The New England Journal of Medicine (NEJM) today published new data from a Phase I clinical trial showing BI 655130, a first-in-class investigational treatment, significantly improved symptoms of generalised pustular psoriasis (GPP), a rare form of psoriasis.1 BI 655130 is a...